Cassava Sciences Inc

NASDAQ:SAVA   4:00:00 PM EDT
33.91
-1.01 (-2.89%)
4:27:37 PM EDT: $34.13 +0.22 (+0.65%)
Earnings Announcements

Cassava Sciences Reports Third Quarter Financial Results

Published: 11/07/2022 14:12 GMT
Cassava Sciences Inc (SAVA) - Q3 Loss per Share $0.51.
Cassava Sciences Reports Third Quarter Financial Results for 2022 and Business Updates.
$174.7 Million Cash and Cash Equivalents at September 30, 2022.
Over 650 Patients Now Enrolled in Phase 3 Clinical Program of Simufilam in Alzheimer's Disease.
New Clinical Data for Simufilam in Alzheimer's Disease Expected.
Q3 Earnings per Share View $-0.48 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.56

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.54

More details on our Analysts Page.